View Item 

Show simple item record

Advances in Thrombolytic Therapy for Acute Myocardial Infarction
dc.contributor.authorTopol, Eric J.en_US
dc.date.accessioned2013-04-08T20:49:26Z
dc.date.available2013-04-08T20:49:26Z
dc.date.issued1987-10en_US
dc.identifier.citationTopol, Eric J. (1987). "Advances in Thrombolytic Therapy for Acute Myocardial Infarction." The Journal of Clinical Pharmacology 27(10). <http://hdl.handle.net/2027.42/97149>en_US
dc.identifier.issn0091-2700en_US
dc.identifier.issn1552-4604en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/97149
dc.publisherBlackwell Publishing Ltden_US
dc.publisherWiley Periodicals, Inc.en_US
dc.titleAdvances in Thrombolytic Therapy for Acute Myocardial Infarctionen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Cardiology, Department of internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan.en_US
dc.identifier.pmid3123526en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/97149/1/j.1552-4604.1987.tb02989.x.pdf
dc.identifier.doi10.1002/j.1552-4604.1987.tb02989.xen_US
dc.identifier.sourceThe Journal of Clinical Pharmacologyen_US
dc.identifier.citedreferenceMinutes of FDA Cardiorenal Advisory Committee Meeting, Bethesda, MD, May 29 1987.en_US
dc.identifier.citedreferenceWerns SW, Shea MJ, Lucchesi BR: Free radicals and myocardial injury: Pharmacologic implications. Circulation 1986; 74: 1 – 5.en_US
dc.identifier.citedreferenceUraizee A, Reimer KA, Murry CE, Jennings RB: Failure of superoxide dismutase to limit size of myocardial infarction after 40 minutes of ischemia and 4 days of reperfusion in dogs. Circulation 1987; 75: 1237 – 1248.en_US
dc.identifier.citedreferenceWerns ST: Strategies to limit reperfusion injury, in Topol EJ (ed): Acute Coronary Intervention. New York, Alan R. Liss, 1987: 263 – 283.en_US
dc.identifier.citedreferenceDarius H, Yanagisawa A, Brezinski ME, et al: Beneficial effects of tissue‐type plasminogen activator in acute myocardial ischemia in cats. J Am Coll Cardiol 1986; 8: 125 – 131.en_US
dc.identifier.citedreferenceJaffe AS: New mechanism of action for tissue‐type plasminogen activator? J Am Coll Cardiol 1986; 8: 132 – 133.en_US
dc.identifier.citedreferenceThe Wall Street Journal, Editorial: Human sacrifice. June 2 1987.en_US
dc.identifier.citedreferenceThe Wall Street Journal, Editorial: The Flat Earth Committee. July 13 1987.en_US
dc.identifier.citedreferenceThe Wall Street Journal, Editorial: The decision against a heart drug. July 13 1987.en_US
dc.identifier.citedreferenceSun M: FDA puts new heart drug on hold. Science 1987; 237: 16 – 18.en_US
dc.identifier.citedreferenceSchlender BR, Waldholz M: Drug on trial—Genentech's missteps and FDA policy shift led to TPA setback. The Wall Street Journal, June 16, 1987.en_US
dc.identifier.citedreferenceKoshland DE: TPA and PDQ. Science 1987; 237: 341.en_US
dc.identifier.citedreferenceYusuf S, Collins R, Peto R, et al: Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: Overview of results on mortality, reinfarction and side‐effects from 33 randomized controlled trials. Eur Heart J 1985; 6: 556 – 585.en_US
dc.identifier.citedreferenceCollen D, Stassen J, Stump DC, Verstraete M: Synergism of thrombolytic agents in vivo. Circulation 1986; 74: 838 – 842.en_US
dc.identifier.citedreferenceCollen D, Stump DC, Van de Werf F: Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. Am Heart J 1986; 58: 1083 – 1084.en_US
dc.identifier.citedreferenceEhrlich HJ, Bang NU, Mattler LE, et al: Biologic properties of a tissue plasminogen activator mutant. Circulation 1986; 74 ( suppl II ): II‐246.en_US
dc.identifier.citedreferenceBode C, Runge MS, Newell JB, et al: Thrombolysis by a fibrin‐specific antibody Fab'‐urokinase conjugate. J Mol Cell Cardiol 1987; 19: 335 – 341.en_US
dc.identifier.citedreferenceTillet WS, Garner RL: The fibrinolytic activity of hemolytic streptococci. J Exp Med 1983; 58: 485 – 502.en_US
dc.identifier.citedreferenceTillett WS, Sherry S: The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin invest 1949; 28: 173 – 190.en_US
dc.identifier.citedreferenceHerrick JB: Clinical features of sudden obstruction of the coronary arteries. JAMA 1912; 59: 2015 – 2020.en_US
dc.identifier.citedreferenceChazov EI, Mateeva LS, Mazaev AV, et al: Intracoronary administration of fibrinolysin in acute myocardial infarction. Ter Arkh 1976; 48: 8 – 19.en_US
dc.identifier.citedreferenceRentrop KP, Blanke H, Karsch KR, Kreuzer H: Initial experience with transluminal recanalization of the recently occluded infarct‐related coronary artery in acute myocardial infarction—comparison with conventionally treated patients. Clin Cardiol 1979; 2: 92 – 105.en_US
dc.identifier.citedreferenceDeWood MA, Spores J, Notske R, et al: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897 – 902.en_US
dc.identifier.citedreferenceFletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S: The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians 1958; 71: 289 – 296.en_US
dc.identifier.citedreferenceStampfer MJ, Goldhaber SZ, Yusuf S, et al: Effect of intravenous streptokinase on acute myocardial infarction. N Engl J Med 1982; 307: 1180 – 1182.en_US
dc.identifier.citedreferenceEuropean Cooperative Study Group: Streptokinase in acute myocardial infarction. N Engl J Med 1979; 301: 797 – 802.en_US
dc.identifier.citedreferenceVan de Werf F, Nobuhara M, Collen D: Coronary thrombolysis with human single‐chain urokinase‐type plasminogen activator (pro‐urokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345 – 348.en_US
dc.identifier.citedreferenceRentrop P, Blanke H, Karsch KR, et al: Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 1981; 63: 307 – 317.en_US
dc.identifier.citedreferenceGanz W, Buchbinder N, Marcus H, et al: Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J 1981; 101: 4 – 13.en_US
dc.identifier.citedreferenceKennedy JW, Ritchie JL, Davis KB, Fritz JK: Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477 – 1482.en_US
dc.identifier.citedreferenceSimoons ML, Brand M V/D, de Zwaan C, et al: Improved survival after early thrombolysis in acute myocardial infarction. Lancet 1985; 11: 578 – 582.en_US
dc.identifier.citedreferenceRentrop KP: Thrombolytic therapy in patients with acute myocardial infarction. Circulation 1985; 71: 627 – 631.en_US
dc.identifier.citedreferenceKhaja F, Walton JA Jr, Brymer JF, et al: Intracoronary fibrinolytic therapy in acute myocardial infarction. N Engl J Med 1983; 308: 1305 – 1311.en_US
dc.identifier.citedreferenceLeiboff RH, Katz RJ, Wasserman AG, et al: A randomized, angiographically controlled trial of intracoronary streptokinase in acute myocardial infarction. Am J Cardiol 1984; 53: 404 – 407.en_US
dc.identifier.citedreferenceRaizner AE, Tortoledo FA, Verani MS, et al: Intracoronary thrombolytic therapy in acute myocardial infarction: A prospective, randomized, controlled trial. Am J Cardiol 1985; 55: 301 – 308.en_US
dc.identifier.citedreferenceRentrop KP, Feit F, Blanke H, et al: Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. N Engl J Med 1984; 311: 1458 – 1463.en_US
dc.identifier.citedreferenceMathey DG, Sheehan FH, Schofer J, Dodge HT: Time from onset of symptoms to thrombolytic therapy: A major determinant of myocardial salvage in patients with acute transmural infarction. J Am Coll Cardiol 1985; 6: 518 – 525.en_US
dc.identifier.citedreferenceSerruys PW, Simoons ML, Suryapranata H, et al: Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1986; 7: 729 – 742.en_US
dc.identifier.citedreferenceAnderson JL, Marshall HW, Bray BE, et al: A randomized trial of intracoronary streptokinase in the treatment of acute myocardial infarction. N Engl J Med 1983; 308: 1312 – 1353.en_US
dc.identifier.citedreferenceAmerican Hospital Association Annual Survey, Washington, DC, 1986.en_US
dc.identifier.citedreferenceBurkey MW, Smith MR, Walsh TE, et al: Relation of effectiveness of intracoronary thrombolysis in acute myocardial infarction to systemic thrombolytic state. Am J Cardiol 1985; 56: 441 – 444.en_US
dc.identifier.citedreferenceRothbard RL, Fitzpatrick PG, Francis CW, et al: Relationship of the lytic state to successful reperfusion with standard‐ and low‐dose intracoronary streptokinase. Circulation 1985; 71: 562 – 570.en_US
dc.identifier.citedreferenceO'Neill W, Timmis G, Bourdillon P, et al: A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty therapy of acute myocardial infarction. N Engl J Med 1986; 314: 812 – 828.en_US
dc.identifier.citedreferenceKennedy JW, Ritchie JL, Davis KB, Fritz JK: Western Washington randomized trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1983; 309: 1477 – 1482.en_US
dc.identifier.citedreferenceKennedy JW, Gensini GG, Timmis GC, Maynard C: Acute myocardial infarction treated with intracoronary streptokinase: A report of the society for cardiac angiography. Am J Cardiol 1985; 55: 871 – 877.en_US
dc.identifier.citedreferenceStadius ML, Maynard C, Fritz JK. et al: Coronary anatomy and left ventricular function in the first 12 hours of acute myocardial infarction: The Western Washington Randomized Intracoronary Streptokinase Trial. Circulation 1985; 72: 292 – 300.en_US
dc.identifier.citedreferenceDavies GJ, Chierchia S, Maseri A: Prevention of myocardial infarction by very early treatment with intracoronary streptokinase. N Engl J Med 1984; 311: 1488 – 1492.en_US
dc.identifier.citedreferenceKhaja F, Walton JA Jr, Brymer JF, et al: Intracoronary fibrinolytic therapy in acute myocardial infarction. N Engl J Med 1983; 308: 1305 – 1311.en_US
dc.identifier.citedreferenceCollen D. Topol EJ, Tiefenbrunn AJ, et al: Coronary thrombolysis with recombinant human tissue‐type plasminogen activator: A prospective, randomized, placebo‐controlled trial. Circulation 1984; 70: 1012 – 1017.en_US
dc.identifier.citedreferenceWilliams DO, Borer J, Braunwald E. et al: Intravenous recombinant tissue‐type plasminogen activator in patients with acute myocardial infarction: A report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73: 338 – 346.en_US
dc.identifier.citedreferenceTopol EJ, Morris D, Smalling R, et al: A multicenter, randomized, placebo‐controlled trial of a new form of intravenous recombinant tissue‐type plasminogen activator (Activase) in acute myocardial infarction. J Am Coll Cardiol 1987; 9: 1205 – 1213.en_US
dc.identifier.citedreferenceGruppo Italiano per Lo Studio Della Streptochinasi Nell'Infarcto Miocardio (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397 – 401.en_US
dc.identifier.citedreferenceISIS Steering Committee: Intravenous streptokinase given within 0‐4 hours of onset of myocardial infarction reduced mortality in ISIS‐2. Lancet 1987; I: 502.en_US
dc.identifier.citedreferenceThe I.S.A.M. Study Group: A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). N Engl J Med 1986; 314: 1465 – 1471.en_US
dc.identifier.citedreferenceMartin GV, Stadius ML. Davis KB, et al: The Western Washington intravenous streptokinase trial: Effects of intravenous streptokinase on vessel patency and left ventricular function. Circulation 1986; 74 ( suppl II ): II‐367.en_US
dc.identifier.citedreferenceWhite H, Brown M, Takayama M, et al: Improved left ventricular function and early survival with intravenous streptokinase: A double‐blind trial. Circulation 1986; 74 ( suppl II ): H‐5.en_US
dc.identifier.citedreferenceSpann JF, Sherry S, Carabello BA, et al: Coronary thrombolysis by intravenous streptokinase in acute myocardial infarction: acute and follow‐up studies. Am J Cardiol 1984; 53: 655 – 661.en_US
dc.identifier.citedreferenceSchroder R, Biamino G, Leitner E‐RV, et al: Intravenous short‐term infusion of streptokinase in acute myocardial infarction. Circulation 1983; 67: 536 – 548.en_US
dc.identifier.citedreferenceHillis LD, Borer J, Braunwald E, et al: High dose intravenous streptokinase for acute myocardial infarction: Preliminary results of a multicenter trial. J Am Coll Cardiol 1985; 6: 957 – 962.en_US
dc.identifier.citedreferenceGold HK, Leinbach RC, Garabedian HD, et al: Acute coronary reocclusion after thrombolysis with recombinant human tissue‐type plasminogen activator: Prevention by a maintenance infusion. Circulation 1986; 73: 347 – 352.en_US
dc.identifier.citedreferenceVerstraete M, Brower RW, Collen D, et al: Double‐blind randomised trial of intravenous tissue‐type plasminogen activator versus placebo in acute myocardial infarction. Lancet 1985; 11: 965 – 969.en_US
dc.identifier.citedreferenceVerstraete M, Bory M, Collen D, et al: Randomized trial of intravenous recombinant tissue‐type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1985; I: 842 – 847.en_US
dc.identifier.citedreferenceThe TIMI Study Group: The thrombolysis in myocardial infarction (TIMI) trial. N Engl J Med 1985; 312: 932 – 936.en_US
dc.identifier.citedreferenceGarabedian HD, Gold HK, Leinbach RC, et al: Comparative properties of two clinical preparations of recombinant human tissue‐type plasminogen activator in patients with acute myocardial infarction. J Am Coll Cardiol 1987; 9: 599 – 607.en_US
dc.identifier.citedreferenceTopol EJ, Califf RM, George BS, et al: A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987; 317: 581 – 588.en_US
dc.identifier.citedreferenceTIMI report: November 1986, Dallas, Texas, George Washington University Symposium.en_US
dc.identifier.citedreferenceBraunwald E, Knatterud GL, Passamani ER, Robertson TL: Announcement of protocol change in thrombolysis in myocardial infarction trial. J Am Coll Cardiol 1987; 9: 467.en_US
dc.identifier.citedreferenceWilliams DO: Preliminary results of the thrombolysis in myocardial infarction (TIMI) trial, in Topol EJ (ed): Acute Coronary Intervention. New York, Alan R. Liss, 1987: 137 – 145.en_US
dc.identifier.citedreferenceSobel BE. Gross RW, Robison AK: Thrombolysis, clot selectivity, and kinetics. Circulation 1984; 70: 160 – 164.en_US
dc.identifier.citedreferenceCollen D, Bounameaux H, de Cock F, et al: Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue‐type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 73: 511 – 517.en_US
dc.identifier.citedreferenceTopol EJ, Bell WR, Weisfeldt ML: Coronary thrombolysis with recombinant tissue‐type plasminogen activator: Hematologic and pharmacologic study. Ann Intern Med 1985; 103: 837 – 843.en_US
dc.identifier.citedreferenceCollen D, Topol EJ: Tissue‐type plasminogen activator, in Topol EJ (ed): Acute Coronary Intervention New York, Alan R. Liss, 1987: 33 – 45.en_US
dc.identifier.citedreferenceMathey DG, Schofer J, Sheehan FH, et al: Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985; 55: 878 – 882.en_US
dc.identifier.citedreferenceAnderson JL, Rothbard RL, Hackworthy RA, et al: Randomized reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) versus intracoronary streptokinase in acute myocardial infarction: Interim report. Circulation 1986; 74: 11 – 6.en_US
dc.identifier.citedreferenceWalker ID, Davidson JF, Rae AP, et al: Acylated streptokinase‐plasminogen complex in patients with acute myocardial infarction. Thromb Haemost 1984; 51: 204 – 206.en_US
dc.identifier.citedreferenceKasper W, Erbe R, Meinertz T, et al: Intracoronary thrombolysis with an acylated streptokinase‐plasminogen activator (BRL 26921) in patients with acute myocardial infarction. JACC 1984; 4: 357 – 363.en_US
dc.identifier.citedreferenceHillis WS, Horning RS, Dunn FG: Coronary reperfusion following single dose intravenous BRL 26921 [abstract]. Circulation 1984; 70 ( suppl II ): II‐28.en_US
dc.identifier.citedreferenceMarder VJ, Rothbard RL, Fitzpatrick PG, et al: Dose response study of intravenous acylated streptokinase: Plasmin complex (BRL26921) in coronary artery thrombosis. Circulation 1984; 70 ( suppl II ): II‐29.en_US
dc.identifier.citedreferenceBeen M, de Bono DP, Muir AL, et al: Clinical effects and kinetic properties of intravenous APSAC‐anisoylated plasminogen‐streptokinase activator complex (BRL 26921) in acute myocardial infarction. Int J Cardiol 1986; 11: 53 – 61.en_US
dc.identifier.citedreferenceMarder VJ, Rothbard RL, Fitzpatrick PG, Francis CW: Rapid lysis of coronary artery thrombi with anisoylated plasminogen: Streptokinase activator complex. Ann Intern Med 1986; 104: 304 – 310.en_US
dc.identifier.citedreferenceVan de Werf F, Nobuhara M, Collen D: Coronary thrombolysis with human single‐chain urokinase‐type plasminogen activator (pro‐urokinase) in patients with acute myocardial infarction. Ann Intern Med 1986; 104: 345 – 348.en_US
dc.identifier.citedreferenceVan de Werf F, Vanhaecke J, de Geest H, et al: Coronary thrombolysis with recombinant single‐chain urokinase‐type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 74: 1066 – 1070.en_US
dc.identifier.citedreferenceShery S: Tissue plasminogen activator (t‐PA): Will it fulfill its promise? N Engl J Med 1985; 313: 1014 – 1017.en_US
dc.identifier.citedreferenceSherry S: Recombinant tissue plasminogen activator (rt‐PA): Is it the thrombolytic agent of choice for an evolving acute myocardial infarction? Am J Cardiol 1987; 59: 984 – 989.en_US
dc.identifier.citedreferenceChesebro JH, Knatterud G, Roberts R, et al: Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142 – 154.en_US
dc.identifier.citedreferenceRao AK: Thrombolysis in myocardial infarction trial (phase I): effect of intravenous tissue plasminogen activator and streptokinase on plasma fibrinogen and the fibrinolytic system. Circulation 1985; 72: III‐416.en_US
dc.identifier.citedreferenceGuerci AD, Gerstenblith G, Brinker JA, et al: A randomized, placebo‐controlled, double‐blinded trial of intravenous tissue plasminogen activator with subsequent randomization to elective coronary angioplasty for acute myocardial infarction. N Engl J Med 1987;(submitted).en_US
dc.identifier.citedreferenceO'Rourke M, Baron D, Keogh A, et al: Randomized placebo controlled double blind trial of intravenous recombinant tissue plasminogen activator initiated within 2.5 hours of symptom onset in acute coronary occlusion. Lancet 1987;(submitted).en_US
dc.identifier.citedreferenceRude RE, Muller JE, Braunwald E: Efforts to limit the size of myocardial infarcts. Ann Intern Med 1981; 95: 736 – 761.en_US
dc.identifier.citedreferenceArntz R, Heitz J, Schafer H, Schroder R: Hemorrheology in acute myocardial infarction: Effects of high dose intravenous streptokinase. Circulation 1985; 72: III‐417.en_US
dc.identifier.citedreferenceJan K, Reinhart W, Chien S, et al: Altered rheological properties of blood following administration of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction. Circulation 1985; 72: III‐417.en_US
dc.identifier.citedreferenceDormandy J, Ernst E, Matrai A, Flute PT: Hemorrheologic changes following acute myocardial infarction. Am Heart J 1982; 104: 1364 – 1367.en_US
dc.identifier.citedreferenceVaughn DE, Loscalzo J: Dissaggregation of platelets: A comparison of tissue plasminogen activator, streptokinase and urokinase. Circulation 1986; 74 ( suppl II ): II‐95.en_US
dc.identifier.citedreferenceSobel BE, Gross RW, Robison AK: Thrombolysis, clot selectivity, and kinetics. Circulation 1984; 70: 160 – 164.en_US
dc.identifier.citedreferenceFung AYM, Rabkin SW: Beneficial effects of streptokinase on left ventricular function after myocardial reoxygenation and reperfusion following global ischemia in the isolated rabbit heart. J Cardiovasc Pharmacol 1984; 6: 429 – 435.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1552-4604.1987.tb02989.x.pdf
Size:
1.781MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.